Stock ALKS ALKERMES PLC
Add to a list
To use this feature you must be a member
Log inSign up

Company Alkermes plc

Equities

ALKS

IE00B56GVS15

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-28 pm EDT 		5-day change 1st Jan Change
23.75 USD -1.12% Intraday chart for Alkermes plc -2.42% -14.38%
May. 23 Cantor Fitzgerald Adjusts Alkermes Price Target to $48 From $43, Maintains Overweight Rating MT
May. 02 UBS Adjusts Price Target on Alkermes to $21 From $23, Maintains Sell Rating MT

Business Summary

Alkermes plc is a global biopharmaceutical company that seeks to develop medicines in the field of neuroscience. The Company has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. It focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. It has a manufacturing facility in Wilmington, Ohio.

Number of employees: 2,100

Sales per Business

USD in Million2022Weight2023Weight Delta
Product
55.3 %
778 69.9 % 920 55.3 % +18.32%
Manufacturing and Royalty
44.7 %
332 29.9 % 743 44.7 % +123.92%
Research and Development
0.0 %
0 0.0 % 0 0.0 % -92.69%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
89.7 %
932 83.8 % 1,492 89.7 % +60.08%
Rest of World
10.2 %
178 16.0 % 170 10.2 % -4.32%
Ireland
0.1 %
2 0.2 % 1 0.1 % -35.54%

Managers

Managers TitleAgeSince
Richard Pops CEO
 Chief Executive Officer 62 91-01-31
Blair Jackson DFI
 Director of Finance/CFO 51 98-12-31
Shane Cooke PSD
 President 61 11-08-31
Sondra Smyrnios CTO
 Chief Tech/Sci/R&D Officer - 19-06-30
Craig Hopkinson CTO
 Chief Tech/Sci/R&D Officer 56 17-05-29
Thomas Harvey CTO
 Chief Tech/Sci/R&D Officer - 04-12-31
Kanchan Relwani CTO
 Chief Tech/Sci/R&D Officer - 16-12-31
Declan O’Connor COO
 Chief Operating Officer - 11-08-31
David Gaffin CMP
 Compliance Officer 52 16-04-30
Markus Haeberlein CTO
 Chief Tech/Sci/R&D Officer - -

Members of the board

Members of the board TitleAgeSince
Richard Pops CEO
 Chief Executive Officer 62 91-01-31
Nancy Snyderman BRD
 Director/Board Member 72 16-05-25
Brian McKeon BRD
 Director/Board Member 61 20-12-09
Dave Daglio BRD
 Director/Board Member - 20-12-09
Shane Cooke BRD
 Director/Board Member 61 11-08-31
Andy Wilson BRD
 Director/Board Member 65 19-09-11
Cato Laurencin BRD
 Director/Board Member 65 21-11-17
Christopher Wright BRD
 Director/Board Member 58 22-05-23
Richard Gaynor BRD
 Director/Board Member 74 19-09-11
Emily Alva BRD
 Director/Board Member 49 21-05-17

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 175,771,015 167,110,486 ( 95.07 %) 6,549,704 ( 3.726 %) 95.07 %

Shareholders

NameEquities%Valuation
BlackRock Advisors LLC
16.16 %
27,347,292 16.16 % 668 M $
Vanguard Fiduciary Trust Co.
11.92 %
20,161,180 11.92 % 493 M $
Wellington Management Co. LLP
8.802 %
14,892,360 8.802 % 364 M $
STATE STREET CORPORATION
5.322 %
9,003,913 5.322 % 220 M $
T. Rowe Price International Ltd.
4.921 %
8,326,256 4.921 % 203 M $
RTW Investments LP
3.579 %
6,054,280 3.579 % 148 M $
Renaissance Technologies LLC
3.480 %
5,887,151 3.480 % 144 M $
Pacer Advisors, Inc.
2.529 %
4,278,563 2.529 % 105 M $
Geode Capital Management LLC
2.212 %
3,742,771 2.212 % 91 M $
Deep Track Capital LP
2.069 %
3,500,000 2.069 % 86 M $

Company contact information

Alkermes Plc

Connaught House 1 Burlington Road

4, Dublin

+

http://www.alkermes.com
address Alkermes plc(ALKS)

Sector

Healthcare
Pharmaceuticals & Medical Research
Biotechnology & Medical Research
Biotechnology & Medical Research
Other Biotechnology & Medical Research

Sales per Business

Sales per region

Ratings for Alkermes plc

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
12
Last Close Price
24.02 USD
Average target price
34.27 USD
Spread / Average Target
+42.68%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ALKERMES PLC Stock Alkermes plc
-14.01% 4.06B
MODERNA, INC. Stock Moderna, Inc.
+53.55% 63.85B
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-2.07% 41.83B
LONZA GROUP AG Stock Lonza Group AG
+40.01% 40.47B
CELLTRION, INC. Stock Celltrion, Inc.
-10.22% 27.17B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+13.65% 26.52B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.46% 18.69B
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+2.77% 12.73B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+22.58% 12.11B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+27.46% 12.07B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. ALKS Stock
  4. Company Alkermes plc